Skadden is advising Gilead Sciences, Inc. on its $5.1 billion transaction with Galapagos NV involving a 10-year global research development collaboration with, and equity investment in, Galapagos NV.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates